stoxline Quote Chart Rank Option Currency Glossary
  
First Wave BioPharma, Inc. (FWBI)
2.96  0.13 (4.59%)    05-16 16:00
Open: 2.93
High: 3.04
Volume: 56,362
  
Pre. Close: 2.83
Low: 2.84
Market Cap: 6(M)
Technical analysis
2024-05-28 4:52:58 PM
Short term     
Mid term     
Targets 6-month :  4.14 1-year :  4.84
Resists First :  3.54 Second :  4.14
Pivot price 2.78
Supports First :  2.79 Second :  2.33
MAs MA(5) :  2.92 MA(20) :  2.8
MA(100) :  4.46 MA(250) :  10.04
MACD MACD :  -0.3 Signal :  -0.4
%K %D K(14,3) :  74 D(3) :  66.8
RSI RSI(14): 45.7
52-week High :  60 Low :  2.33
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ FWBI ] has closed below upper band by 14.9%. Bollinger Bands are 80.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.04 - 3.06 3.06 - 3.07
Low: 2.81 - 2.82 2.82 - 2.84
Close: 2.94 - 2.96 2.96 - 2.98
Company Description

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Headline News

Thu, 16 May 2024
First Wave BioPharma Changes Name to Entero Therapeutics - Yahoo Finance

Fri, 10 May 2024
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market - GlobeNewswire

Wed, 27 Mar 2024
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Mon, 25 Mar 2024
First Wave BioPharma stock reinstated at neutral by H.C. Wainwright - Investing.com

Thu, 14 Mar 2024
Why Is First Wave BioPharma (FWBI) Stock Up Today? - InvestorPlace

Thu, 14 Mar 2024
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 2 (M)
Held by Insiders 7.6 (%)
Held by Institutions 4 (%)
Shares Short 47 (K)
Shares Short P.Month 55 (K)
Stock Financials
EPS -47.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.3
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -160 %
Return on Equity (ttm) -497.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -7.76
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -0.07
PEG Ratio 0
Price to Book value 1.28
Price to Sales 0
Price to Cash Flow -0.49
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android